FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE and DRUG INEFFECTIVE

Overview

DRUG INEFFECTIVE is the #2 most commonly reported adverse reaction for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 3,162 FDA adverse event reports linking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to DRUG INEFFECTIVE. This represents approximately 4.5% of all 70,190 adverse event reports for this drug.

Patients taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DRUG INEFFECTIVE is moderately reported among FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE users, representing a notable but not dominant share of adverse events.

Other Side Effects of FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

In addition to drug ineffective, the following adverse reactions have been reported for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:

• DYSPNOEA — 5,246 reports
• PRODUCT DOSE OMISSION ISSUE — 2,933 reports
• WRONG TECHNIQUE IN DEVICE USAGE PROCESS — 2,925 reports
• PRODUCT COMPLAINT — 2,598 reports
• COUGH — 2,510 reports
• DEATH — 2,244 reports
• PNEUMONIA — 1,862 reports
• ASTHMA — 1,558 reports
• CHRONIC OBSTRUCTIVE PULMONARY DISEASE — 1,444 reports
• FATIGUE — 1,210 reports

Other Drugs Associated with DRUG INEFFECTIVE

The following drugs have also been linked to drug ineffective in FDA adverse event reports:

Does FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE cause DRUG INEFFECTIVE?

DRUG INEFFECTIVE has been reported as an adverse event in 3,162 FDA reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DRUG INEFFECTIVE with FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

DRUG INEFFECTIVE accounts for approximately 4.5% of all adverse event reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it one of the most commonly reported side effect.

What should I do if I experience DRUG INEFFECTIVE while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

If you experience drug ineffective while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages